SR144528 is primarily used in research settings to study the endocannabinoid system, particularly as a selective antagonist for the CB2 receptor. It helps scientists understand the role of CB2 receptors in immune responses, inflammation, and pain regulation. This compound is valuable in preclinical studies aimed at exploring potential therapeutic targets for conditions like autoimmune diseases, neuropathic pain, and chronic inflammation. Additionally, it aids in distinguishing the effects of CB2 receptor activity from those of CB1 receptors, providing insights into the development of targeted treatments with minimized side effects.